Status:
RECRUITING
Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
Lead Sponsor:
Mohammad Hussien Tantawy Soliman
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and r...
Detailed Description
DAPA was approved for HF patients, but there is no sufficient data about its efficacy on patients with AMI and if it can protect from the development of HF after AMI. the investigators aim to investi...
Eligibility Criteria
Inclusion
- Patients with ST-elevation myocardial infarction (STEMI).
- STEMI was defined according to the Fourth Universal Definition of AMI.
- 18 - 80 years of age.
- Diabetics or non-diabetics.
- eGFR \> 45 ml/min/1.73m2.
- Blood pressure before first drug dosing \>110/70 mmHg.
Exclusion
- Cardiogenic shock.
- Hypoglycemia.
- History of diabetic ketoacidosis.
- Genital and urinary infections.
- History of AMI.
- Stent thrombosis.
- Previous coronary artery bypass surgery.
- Severe hepatic insufficiency.
- Advanced cancer patients.
- Blood pH \< 7.32.
- Known allergy to SGLT-2 inhibitors.
- Hemodynamic instability.
- Females of childbearing potential without adequate contraceptive methods.
- Patients currently on or have received any SGLT-2 inhibitors.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06009874
Start Date
October 1 2023
End Date
August 1 2026
Last Update
August 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohammad Soliman
Shibīn al Kawm, Menofia, Egypt, 32741